What services will generate the maximum amount of profits in the long run based on the company's current level of penetration of a specific therapeutic area.
What services are of high value, given the degree of innovation represented by company products, the cost and complexity of care regimens, and the nature of the target disease states?
What services can products in the portfolio "afford", given the revenue potential?
What services does the company have the internal capabilities to execute effectively?
Responding to customer concerns, specifically dosing information
Responding to calls from healthcare professionals, specifically product related inquiries.
Responding to internal concerns regarding specific products
Providing medical information to the external community
Standardized operating procedures
Experience with the development of the product
Robust systems and tools
The Robin Hoods of the Pharma world.
Dealing with negligent behavior during clinical drug trials.
Dealing with the enforcement of restrictions by the FDA during clinical trials.
Dealing with reports of adverse events in patients during clinical trials.
Medical Affairs controls all Preclinical Research
Medical Affairs provides value perspective/vision based on its understanding of alternative products and unmet medical needs
Medical Affairs acts as the liaison between the Regulatory Department and the Discovery team to ensure that the two divisions are working together to meet the strategic needs of the company.
Medical Affairs plays no role in Preclinical Research.
Medical Affairs is consulted when the trial is moving between the phases to provide strategic planning advice.
Medical Affairs is in charge of everything related to registrational clinical trials.
Medical Affairs plays no role in registrational clinical trials.
Limited primarily to the recruitment of trial investigators.
Medical Affairs plays no role in non-registrational clinical trials.
Medical Affairs assumes responsibility for all post approval studies.
Medical Affairs plays a limited governance role in post approval trials.
Medical Affairs is on-call and provides assistance when necessary in post approval trials.
Studies that are a necessary component of the application for regulatory approval.
Additional studies that piggy back onto the normal phase 3 trials that cropped up due to significant reports of adverse events.
Studies conducted after a submission to regulators for marketing approval but before that approval is actually granted.
Phase 3 studies that are being repeated due to the discovery on an off-label usage of the product.
To increase local market presence and experience
To evaluate product use in a variety of "real-world" settings
To evaluate off-label usage of the product
To enhance product differentiation
To gather additional safety information
The conclusions drawn from the trial must be the independent judgment of the investigating physicians.
Affiliation with the company who created the product would bias the reputation of the study.
The company is only allowed to be involved with the actual conduct of the trial if they are supplying the test material.
A and C
B and C
A type of phase 4 clinical trial.
A company-sponsored study.
A study to investigate a new application of an approved drug without submission of an IND.
A study regarding a different use of the product conducted by a competitor under the approval of the original product owner.
Health economics and outcomes studies
Cost-benefit ratio in financial terms
Medical Affairs has nothing to do with product messaging.
Medical Affairs is in charge of product messaging.
Medical Affairs can impact the brand messaging by offering medical and scientific insights.
Medical Affairs defines the promotional product messages.
Incidence and intensity of adverse effects
Adherence to the recommended drug regimen.
What the cost-benefit equation is in financial terms.
Overall quality of life.
Medical Communications is responsible for disseminating information that supports the positive outcomes of the company's products.
Medical Communications acts as a relay center between Medical Affairs and the outside world, performing triage and routing calls from healthcare professionals and patients.
Medical Communications is responsible for the brand messaging and marketing materials for a new product.
Medical Communications is responsible for communicating unbiased non-promotional information the company's products.
How to brand and market a new product.
Determining when and where to publish information about a product.
When articles are published about a product, how to use the peer-reviewed literature to the advantage of a drug.
The overall plan of the NDA application submitted to the FDA.
The package insert.
Summaries of published articles, or abstracts.
Oversized summaries of preliminary trial results, or posters.
The KOL's are plugged into the industry and understand where gaps are for the pharma company to exploit.
The opinion of a KOL carries much weight with the community and can influence healthcare officials with prescribing power around them.
KOL's will be more apt to prescribe a drug that they helped develop.
Pharma companies can use the expertise of KOL's to help refine their lead series to formulate a more promising compound.
The head of Medical Affairs
The most famous/prominent scientists on staff at the particular pharma company.
The Medical Liaison
KOL's may educate fellow physicians about therapeutic options they consider the best.
KOL's can offer insights into treatment issues and unmet needs inside the therapeutic area.
KOL's may provide disease-state education to their fellow physicians/build awareness
KOL's run the external continuing education programs as a representative of the sponsoring pharma company.
KOL's may agree to serve as investigators on clinical trials thereby increasing the impact of such trials on the perception of other healthcare professionals.
A large supply of alcohol, hot girls, money, and other niceties that are good to have on hand when trying to influence KOLs.
A smooth, sales-guy persona who can sell ice to an eskimo.
Their access to the board of governors at the target AMC to influence the prescribing physicians from the top down.
Their demonstrated mastery of the latest research related to a therapeutic area, disease state, and drug.